Takeda Feels Confident Of No Entyvio Biosimilars Until Early 2030s
Japanese Firm Notes Challenges In Developing IBD Biologics
Biosimilar vedolizumab rivals to Takeda’s Entyvio blockbuster will not materialize in the current decade, the Japanese originator has forecasted as part of a significantly extended IP landscape.
